

Informazione Regolamentata n. 20106-2-2023	Data/Ora Ricezione 04 Gennaio 2023 07:52:06	Euronext Star Milan
--	---	---------------------

Societa' : PHARMANUTRA  
Identificativo : 171123  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN01 - Sarti  
Tipologia : REGEM  
Data/Ora Ricezione : 04 Gennaio 2023 07:52:06  
Data/Ora Inizio : 04 Gennaio 2023 07:52:10  
Diffusione presunta  
Oggetto : PR - Pharmanutra - New commercial  
agreements

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: NEW DISTRIBUTION AGREEMENTS IN INDONESIA, KUWAIT AND MEXICO

***PT Pyridam Farma Tbk, PharmaLife Co. and SMS Pharma will introduce SiderAL® and Cetilar® products in the Indonesian, Kuwaiti and Mexican markets, hence expanding the presence of PharmaNutra technologies in South-East Asia, the Arabian Peninsula and Central America.***

Pisa, 4 January 2023 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialised in mineral and iron-based nutritional supplements and medical devices for muscles and joints health, is pleased to announce the signing of three new international trade agreements for the distribution of its SiderAL® and Cetilar® lines in the Republic of Indonesia, Kuwait and Mexico.

As far as Indonesia is concerned, the new partner **PT Pyridam Farma Tbk.** will distribute two nutritional supplements containing Sucrosomial® Iron, **SiderAL® F30** (PharmaNutra brand) and **SiderAL® Gocce P** (Junia Pharma brand). These products, the former intended for an adult target and the latter for the paediatric sector, will become part of the Pyridam Farma portfolio, which includes international products of companies of the calibre of Eli Lilly, Amgen, Astra Zeneca and Lundbeck. As a matter of fact, the company has operated in the Indonesian pharmaceutical sector for more than 40 years and, thanks to its network of more than 320 medical science liaisons, its production and marketing activities cover all 34 of the country's provinces, with a potential usership of 275 million inhabitants (the Republic of Indonesia has the fourth highest population in the world, after China, India and USA).

As regards Kuwait, the agreement was concluded with **PharmaLife Co.**, a company that distributes medical devices, food supplements, medical equipment and natural products and is already partner to important Italian and foreign companies. The agreement is particularly relevant because, despite operating in a smaller territorial context than Indonesian giant Pyridam Farma, PharmaLife Co. will be placing five PharmaNutra products and one Junia Pharma product on the market, specifically: **Cetilar® Cream, Cetilar® Patch, SiderAL® Folic 20 sticks, SiderAL® Folic 30 cps, SiderAL® Forte Int 20 cps and SiderAL® Gocce P.**

In Mexico, PharmaNutra has finalised a new partnership with the company **SMS Pharma**, whose core business focuses on developing national sales networks specialising in the distribution of pharmaceutical

and health products. The contract with SMS Pharma will result, in the course of 2023, in the marketing of the nutritional supplements **SiderAL® Forte 15 mg 30 cps** and **SiderAL® Folic 21 mg 20 sticks** (PharmaNutra), as well as **SiderAL® Gocce P** (Junia Pharma) throughout Mexico.

With the conclusion of these new distribution agreements, the PharmaNutra Group can now count on 47 distributors in 70 countries across Europe, Asia, Latin America and Africa.

*“Following the distribution agreements in Denmark and Albania concerning SiderAL® products, it is a pleasure to announce the start of three new partnerships of strategic importance, within the scope of the PharmaNutra Group’s international expansion agenda”, states Carlo Volpi, COO of the PharmaNutra Group. “Indonesia is a market with huge potential, the country with the fourth largest population in the world: it has been a long journey, but we are now ready to reap the rewards of the outstanding work done by our International Business Development team. As regards Kuwait and Mexico, although the country size is different, the agreements are particularly significant from the perspective of commercial positioning, as they make provision for the distribution of our two leading product families, SiderAL® and Cetilar®, and therefore we are particularly optimistic regarding future developments in these countries.”*

**PharmaNutra S.p.A.**

Founded and led by Chairman Andrea Lacorte and Deputy Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique food supplements and innovative nutrition devices by carrying out the entire production process, from the proprietary starting materials through to the finished product. The effectiveness of its products is demonstrated by a wealth of scientific evidence, including 135 publications involving more than 7000 subjects. The Group distributes and places its products on the market in Italy and abroad. Within Italy, sales activities are carried out through a network of over 160 medical science liaisons serving the medical profession, as well as focusing on the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales activities are guaranteed abroad in 70 different countries through 47 partners chosen amongst the best pharmaceutical companies. PharmaNutra is a market leader in the manufacture of dietary supplements containing iron with its SiderAL® brand, where it boasts important patents covering its Sucrosomial® Technology. Over the years, the Group has developed a precise strategy regarding the management and production of intellectual property, based on integrated management of all the various components: proprietary starting materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa, Italy

Tel. +39 050-7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan, Italy

Tel. +39 02-83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-2

Numero di Pagine: 5